The AML treatment landscape has significantly changed in recent years with the approval of
targeted therapies in the front-line and relapsed/refractory settings, including inhibitors of …

Recent studies on pediatric acute myeloid leukemia (pAML) have revealed pediatric-specific
driver alterations, many of which are underrepresented in the current classification schemas …

Aberrant expression of HOX and MEIS1 family genes, as seen in KMT2A-rearranged,
NUP98-rearranged, or NPM1-mutated leukemias leads to arrested differentiation and …

PURPOSE Revumenib, an oral, small molecule inhibitor of the menin-lysine
methyltransferase 2A (KMT2A) interaction, showed promising efficacy and safety in a phase …

The protein menin is encoded by the MEN1 gene and primarily serves as a nuclear scaffold
protein, regulating gene expression through its interaction with and regulation of chromatin …

Acute myeloid leukemia (AML) is an aggressive hematological malignancy with a
heterogeneous molecular landscape. In the pediatric context, the NUP98 gene is a frequent …

Introduction The combined use of the BCL-2 inhibitor venetoclax with azacitidine now is the
standard of care for patients with acute myeloid leukemia (AML) unfit for intensive …

Response and Resistance to Menin Inhibitor in UBTF–Tandem Duplication AML | New England
Journal of Medicine Skip to main content The New England Journal of Medicine homepage …

Simple Summary Proteins serve as the primary regulators of cellular functions, and the
development of new drugs largely focuses on target proteins that play crucial roles in …

Recent extensive studies on the genomic and molecular profiles of acute myeloid leukemia
(AML) have expanded the treatment options, including, a range of compounds represented …